摘要:
The present invention relates to a genetically encoded FRET-based biosensor to monitor the activity of matrix metalloproteinase 9 (MMP-9). MMP-9 is an extracellular acting endopeptidase implicated in both physiological and pathological processes. A genetically encoded FRET biosensor anchored in the cellular membrane allows studying the proteolytic activity of MMP-9 with high spatiotemporal resolution at the exact region of MMP-9 action on the cell. Applicability of the biosensor, both in vitro and in vivo in living cells, has been demonstrated by ratiometric analysis of cleavage of the biosensor by a purified auto-activating mutant of MMP-9.
摘要:
The present invention relates to panels of biomarker microRNAs for use in methods of diagnosing Alzheimer's disease and related diseases and conditions in a subject. The methods involve assessing the level of said biomarker microRNA(s) in subject blood sample. The invention also relates to kits comprising said panels of biomarker microRNAs, methods of diagnosing Alzheimer's disease and to the use of said panels of biomarker microRNAs in diagnosis.
摘要:
The present invention is related to use of marimastat or a pharmaceutically acceptable salt, solvate or polymorph thereof in preventing or treating epileptogenesis in a subject that suffered a brain insult. Said brain insult is a stroke, traumatic brain injury, or a result of status epilepticus, evoked by structural or metabolic reasons. Marimastat or a pharmaceutically acceptable salt thereof is administered preferably within the first 24 hours after induction of epileptogenesis.
摘要:
CacyBP/SIP interacts with several targets, including tubulin, and was shown to play a role in the organization of microtubules. To better understand the involvement of CacyBP/SIP in cytoskeletal physiology and pathophysiology, the neuronal redistribution and possible function of CacyBP/SIP in Alzheimer disease (AD) pathology were investigated. CacyBP/SIP exhibits phosphatase activity towards phosphorylated tau, which suggests it might play a role in AD pathology specifically involving tau protein. Therefore, CacyBP/SIP may be useful in the diagnosis and treatment of AD.
摘要:
The present invention relates to diagnostic and therapeutic applications of Grainyhead-like 1 (Grhll) gene related to regulation of blood pressure in mammals. In particular, the subject of the invention is an in vitro method of diagnosis of hypo- or hypertension or a hypo- or hypertension predisposition, the medical use of agents related to Grhll gene and Grainyhead-like 1 transcription factor (GRHLl) for treatment of hypo- or hypertension, use of Grhll -/- , Grhll +/- and/or Grhll +/+ mice and a method of screening drugs against hypo- and hypertension.
摘要:
The present invention is related to use of marimastat or a pharmaceutically acceptable salt, solvate or polymorph thereof in preventing or treating epileptogenesis in a subject that suffered a brain insult. Said brain insult is a stroke, traumatic brain injury, or a result of status epilepticus, evoked by structural or metabolic reasons. Marimastat or a pharmaceutically acceptable salt thereof is administered preferably within the first 24 hours after induction of epileptogenesis.